Healthcare Industry News: rosacea
News Release - October 10, 2006
Valeant Pharmaceuticals Ltd. to Promote and Distribute Intendis Dermatological Products in the United Kingdom
New Agreement Enables Valeant to Offer Clinicians Wider Range of Skin TreatmentsBASINGSTOKE, United Kingdom--(HSMN NewsFeed)--Valeant Pharmaceuticals Ltd. today announced that it has signed an agreement with Intendis GmBH whereby Valeant will sell a range of Intendis dermatological products, including Finacea®, a topical treatment for rosacea, which was launched on September 18, 2006, in the United Kingdom (U.K.). This distribution agreement, which was effective on September 1, 2006, enables Valeant to broaden its offering of dermatological products in the U.K.
"Valeant currently has a strong portfolio of dermatology products in the U.K., including Dermatix® and Efudex®," said Chuck Bramlage, president of Valeant Pharmaceuticals' Europe, Middle East and Asia division. "This agreement expands our product portfolio and allows us to offer clinicians a range of treatments for many dermatological disorders. In addition, it enables Valeant to capitalize on the growth opportunity in one of the world's largest dermatology markets."
In addition to Finacea® (15% azelaic acid gel), Valeant will support all other Intendis products in the U.K., including the 30g formulation of Skinoren® Cream (20% azelaic acid cream), an acne treatment; Scheriproct®, a treatment for hemorrhoids, available as an ointment (30g) or a pack of 12 suppositories; and Ultrabase®, a moisturising cream available in a 50g tube or a 500g pump dispenser.
About Valeant
Valeant Pharmaceuticals Ltd is a subsidiary of Valeant Pharmaceuticals International, a global specialty pharmaceutical company based in the United States that develops, manufactures and markets a broad range of pharmaceutical products primarily in the areas of neurology, infectious disease and dermatology, and whose stock is publicly-traded on the New York Stock Exchange under the ticker symbol "VRX." More information about Valeant can be found at www.valeant.com.
Source: Valeant Pharmaceuticals
Issuer of this News Release is solely responsible for its
content.
Please address inquiries directly to the issuing company.
